ENDRA Life Sciences Inc. (NDRA) Financial Statements
Industry: Electromedical & Electrotherapeutic Apparatus
In fiscal 2025, ENDRA Life Sciences reported revenue of $0. Net income was -$7.0M, or -$8.93 per diluted share. Operating activities generated -$5.2M of cash, leaving -$5.2M of free cash flow. At fiscal year end, ENDRA Life Sciences held $3.9M in total assets against $1.6M in total liabilities.
Open the full interactive ENDRA Life Sciences financials → Quarterly statements, key ratios, valuation history and price charts.
ENDRA Life Sciences Key Stats
| Share Price | $5.04 |
|---|---|
| Market Cap | $12.5M |
| 52-Week Range | $3.26 – $8.12 |
| Shares Outstanding | 1.3 million (basic, 2026 Q2) |
ENDRA Life Sciences Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | — | — | — | — | — |
| Operating Income | -$11.5M | -$11.5M | -$13.2M | -$10.5M | -$10.8M | -$5.8M |
| Pre-Tax Income | -$11.7M | -$11.2M | -$13.2M | -$10.1M | -$11.5M | -$7.0M |
| Income Tax | $0 | $0 | $0 | $0 | $0 | — |
| Net Income | -$11.7M | -$11.2M | -$13.2M | -$10.1M | -$11.5M | -$7.0M |
| Diluted EPS | -$22050.00 | — | — | — | -$56.94 | -$8.93 |
ENDRA Life Sciences Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$1.6M | -$3.2M | -$1.3M | $159,944 |
| Diluted EPS | -$2.10 | -$4.03 | -$1.09 | $0.06 |
ENDRA Life Sciences Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Current Assets | $8.2M | — | $8.5M | $3.0M | $3.4M | $967,969 |
| Total Assets | $8.8M | $10.6M | $9.3M | $6.8M | $4.5M | $3.9M |
| Current Liabilities | $986,663 | — | $1.7M | $903,095 | $605,230 | $750,956 |
| Total Long-Term Debt | $337,084 | — | $365,919 | $29,800 | $29,800 | — |
| Total Liabilities | $1.6M | — | $2.1M | $1.1M | $1.9M | $1.6M |
| Shareholders' Equity | $7.2M | $10.8M | $7.2M | $5.7M | $2.6M | $2.3M |
ENDRA Life Sciences Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$10.7M | -$11.1M | -$12.8M | -$9.5M | -$7.4M | -$5.2M |
| Cash From Investing | -$75,333 | -$45,000 | -$202,577 | -$24,721 | -$12,796 | -$3.0M |
| Cash From Financing | $11.9M | $13.4M | $8.4M | $7.5M | $7.8M | $5.7M |
| Free Cash Flow | -$10.8M | -$11.2M | -$13.0M | -$9.6M | -$7.4M | -$5.2M |
Figures from ENDRA Life Sciences' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full ENDRA Life Sciences financials page for every line item.
ENDRA Life Sciences Company Profile
| Ticker | NDRA |
|---|---|
| Exchange | Nasdaq |
| Industry | Electromedical & Electrotherapeutic Apparatus |
| Headquarters | Ann Arbor, Michigan |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001681682 |
Frequently Asked Questions
What was ENDRA Life Sciences' revenue in fiscal 2025?
ENDRA Life Sciences (NDRA) reported revenue of $0 for fiscal 2025.
What is ENDRA Life Sciences' annual revenue history?
ENDRA Life Sciences' annual revenue by fiscal year: 2020: $0; 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was ENDRA Life Sciences' net income in fiscal 2025?
ENDRA Life Sciences reported net income of -$7.0M for fiscal 2025.
What was ENDRA Life Sciences' earnings per share (EPS) in fiscal 2025?
ENDRA Life Sciences' diluted EPS was -$8.93 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did ENDRA Life Sciences generate in fiscal 2025?
ENDRA Life Sciences generated -$5.2M of free cash flow in fiscal 2025.
What was ENDRA Life Sciences' revenue last quarter?
In its most recent reported quarter (2026 Q2), ENDRA Life Sciences reported revenue of $0.
How many shares of ENDRA Life Sciences are outstanding?
ENDRA Life Sciences reported a weighted average of 1.3 million basic shares outstanding in 2026 Q2.
What is ENDRA Life Sciences' market cap?
Based on its latest closing price, ENDRA Life Sciences (NDRA) has a market capitalization of about $12.5M.
When does ENDRA Life Sciences' fiscal year end?
ENDRA Life Sciences' fiscal year end, as registered with the SEC, is December 31.
Where is ENDRA Life Sciences headquartered?
ENDRA Life Sciences lists its business address in Ann Arbor, Michigan in its SEC filings.
ENDRA Life Sciences Competitors & Similar Companies
See all 23 Electromedical & Electrotherapeutic Apparatus companies →